Radiation Therapy in the Management of Early Stage Breast Cancer in the Geriatric Population - #48

Patients who undergo breast conserving surgery and are committed to take anti-endocrine therapy for five years have a low risk of in-breast recurrence. While it may be safely omitted from breast conserving therapy, radiation therapy will reduce that risk. Criteria for this approach include:

Patients over age 70, and may be considered in low risk patients as young as 65

Small tumors (generally 2cm or less) and only subclinical axillary metastasis

Low grade

Estrogen and progesterone receptor positive

Tumor resected with negative margins

Patients who will be compliant with surveillance mammograms and anti-endocrine therapy

All patients being considered for this approach should have consultation with a radiation oncologist to discuss the relative merits of treatment in this setting and be willing to accept a slightly higher risk of in-breast recurrence. Patients who do opt for radiation therapy should be strongly considered for shorter treatment regimens such as accelerated whole breast radiation or accelerated partial breast irradiation.

Breast conserving therapy has become the preferred method of treatment for many patients with early stage breast cancer. For most patients, this consists of segmental mastectomy (i.e. ‘lumpectomy) followed by radiation therapy. However, some geriatric patients with early stage breast cancer may be treated successfully with breast conserving surgery alone.

Breast cancers in the geriatric population are more likely to have tumors with indolent features such as high rates of hormone receptor expression and higher rates of low grade tumors. These factors are associated with a lower risk of recurrence after breast conserving surgery without radiation. A phase III randomized trial was conducted by the Cancer Leukemia Group B (CALGB www.calgb.org) to determine if radiation therapy could be safely omitted in patients over the age of 70 with small tumors. At 10 years from surgery, 90% of patients treated with surgery and tamoxifen were without locoregional recurrence compared to 98% of patients treated with surgery, tamoxifen and radiation therapy. This result was statistically significant. There were no differences in rates of distant metastasis, overall survival or subsequent mastectomy between the two groups. This study suggests that while radiation reduces the risk of breast cancer recurrence in this population, the absolute magnitude of this risk reduction is relatively small.

On this study, the vast majority of these patients were white (91%), and had tumors smaller than 2cm (98%) that were estrogen receptor positive (97%). Patients required were to be clinically node negative before enrolling on the study. It is important to understand these selection criteria when considering omission of radiation.

There are other large data sets that have confirmed this finding. In an analysis of the SEER database, the benefit of radiotherapy was shown to diminish with patient age. Specifically, patients over the age of 75 who were pathologically node negative and had low grade disease derived no benefit from radiation. However, in patients 70-74, there remained a benefit associated with radiation therapy that was statistically significant. Furthermore, this benefit was comparable to the benefit of other well accepted medical therapies, such as antihypertensive treatment for the prevention of cardiovascular events or bisphosphonate therapy for the prevention of fracture.

Another issue to discuss with patients when considering this approach is utilization of anti-endocrine therapy. On the CALGB study, patients were required to take tamoxifen. However, it is well established that compliance with this medication is diminished outside the setting of a clinical trial. This is significant because anti-endocrine therapy reduces the risk of local recurrence. If this aspect of treatment is omitted, one might not reach the favorable outcomes seen on the CALGB study. In one series investigating this issue, as many as 50% of patients were found to be non-compliant with anti-endocrine therapy. That risk of non-compliance increased with age. Hence when considering the omission of radiation therapy, patients must be reliable and understand the importance of continuing anti-endocrine therapy.

Users are free to download and distribute Geriatric Fast Facts for informational, educational and research purposes only. Citation: Adam Currey MD, Colleen Lawton MD, Steve Denson MD - Fast Fact #48: Radiation Therapy in the Management of Early Stage Breast Cancer in the Geriatric Population. October 2014. See Term of Use for additional information.

Disclaimer: Geriatric Fast Facts are for informational, educational and research purposes only. Geriatric Fast Facts are not, nor are they intended to be, medical advice. Health care providers should exercise their own independent clinical judgment when diagnosing and treating patients. Some Geriatric Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.

Terms of Use: Geriatric Fast Facts are provided for informational, educational and research purposes only. Use of the material for any other purpose constitutes infringement of the copyright and intellectual property rights owned by the specific authors and/or their affiliated institutions listed on each Fast Fact. By using any of this material, you assume all risks of copyright infringement and related liability. Geriatric Fast Facts may not be reproduced or used for unauthorized purposes without prior written permission, which may be obtained by submitting a written request to: Medical College of Wisconsin, Dept. of Medicine, Division of Geriatrics and Gerontology, 8701 Watertown Plank Road, Milwaukee, WI 53226. Note the Geriatric Fast Facts may contain copyrighted work created under contract with government agencies, foundations, funding organizations and commercial companies, etc. If a particular author places further restrictions on the material, you must honor those restrictions regardless of whether such restrictions are described in this mobile app.